3M Drug Delivery Systems 3 Introduction A combination MDI product has been developed containing two active drug substances (designated as A and B) in solution,

Slides:



Advertisements
Similar presentations
Dr. Birgit Schmauser, BfArM, Bonn
Advertisements

Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
Analytical Method Development and Validation
Modification and Validation of Diesel Particulate Matter Cassette for PM-1.0 Sampling at Different Flow Rates Saulius Trakumas and Peter Hall SKC Inc.,
Profile Analysis of Cascade Impactor Data: An Alternative View Andrew R Clark, Ph.D. Orally Inhaled and Nasal Drug Products Subcommittee of the Advisory.
October 30 Do Now Q: Announcements: Important Dates: (that means…write it down in your calendar)
Statistical Approaches to Addressing the Requirements of the New FDA Process Validation Guidance for Small Molecules 1 Jason Marlin, MS/T Statistics, Eli.
By Timina Olive Kayaviri Supervisor : Dr. Amugune
CONCENTRATION UNITS FOR AEROSOLS Yves Alarie, Ph.D Professor Emeritus U niversity of Pittsburgh,USA.
PHARM 462 PART / /31 Good Manufacturing Practices (GMP) VALIDATION of ANALYTICAL TEST METHODS.
World Health Organization
Determine impurity level in relevant batches1
Brake Pad Wear Debris Characterization Mark A. Schlautman, Ph.D Christos Christoforou, Ph.D. Ashley Haselden School of the Environment Clemson University.
Introduction to Inference Estimating with Confidence Chapter 6.1.
PK and PD Studies for Systemic Exposure of Locally Acting Drugs Industry View Lester I. Harrison, PhD Division Scientist 3m Pharmaceuticals.
FDA Nasal BA/BE Guidance Overview
DIFFICULTIES ASSOCIATED WITH COMPOUNDING METERED-DOSE INHALERS AND DRY POWDER INHALERS Brian Rogers, Ph.D. Office of New Drug Chemistry Center for Drug.
Venkata Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
1 14 Design of Experiments with Several Factors 14-1 Introduction 14-2 Factorial Experiments 14-3 Two-Factor Factorial Experiments Statistical analysis.
Best Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables PQRI Leachables & Extractables Working Group VI. Characterization.
Validation of Analytical Method
Simultaneous quantification of bergenin, catechin, and gallic acid from Bergenia ciliata and Bergenia ligulata by using thin-layer chromatography 张 慧.
The following minimum specified ranges should be considered: Drug substance or a finished (drug) product 80 to 120 % of the test concentration Content.
Team Members: Joe Bothwell Communicator Kelly ToyTeam Leader Jon Cappel BWIG Karim Mahamud BSAC.
2015 MBSW1 Quality Assurance Test of Delivered Dose Uniformity of Multi-dose Spray and Inhalation Drug Products Drs. Yi Tsong 1, Xiaoyu (Cassie) Dong*
Analytical considerations in the dissolution testing of oral modified release products Graham Clarke Bristol-Myers Squibb Moreton, UK The British Pharmaceutical.
Mosby items and derived items © 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 3 Administration of Aerosolized Agents.
Bioavailability Dr Mohammad Issa.
1 ORALLY INHALED AND NASAL DRUG PRODUCTS FOR LOCAL ACTION Current FDA BA/BE Background and Issues Wallace P. Adams, Ph.D. OPS/CDER/FDA OINDP Subcommittee.
Inhalation Devices Heba Abd El-fattah Sabry Pharm D.
Validation Defination Establishing documentary evidence which provides a high degree of assurance that specification process will consistently produce.
Aerosols Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
1 Dose Content Uniformity for Aerosol Products Wallace P. Adams, Ph.D. OPS/IO Advisory Committee for Pharmaceutical Science 13 March 2003 Rockville, MD.
Inhalation Toxicology Support Optimisation David Howie April 2014.
Introduction What is a Biowaiver?
1 PTIT for DCU of OINDP: Approaches to Resolution of Identified Issues Wallace P. Adams, Ph.D. OPS/IO Advisory Committee for Pharmaceutical Science 21.
Malaysia, EVALUTION OF DOSSIERS IN WHO- PREQUALIFICATION PROJECT MULTISOURCE TB-DRUGS Evaluation of bioavailability/bioequivalence data Based,
Pharmaceutical Calculations: The International System of Units
Orally Inhaled and Nasal Drug Products Subcommittee Introduction and Objectives Eric B. Sheinin Deputy Director Office of Pharmaceutical Science Center.
FLEMINGTON PHARMACEUTICAL CORPORATION Develops therapeutic entities in Lingual Spray Delivery Systems!
Sarah D’Oyley – 3M Health Care Ltd, Loughborough Louisa Nelmes, Chris Blatchford – 3M Health Care Ltd, Loughborough (contact authors) The size of particles.
Jean Kelly 1, Steve Stein 1, Tom Robison 1, Zhaolin Wang 1, Allan Bohlke 1, John Simons 1, Jacqueline Ganser 1,Tucker Silberhorn 1, Randy Bay 2 ; 1 3M.
I add the analysts, etc. Mike Needham, Phil Cocks and Georgina Fradley 3M Healthcare Ltd., Loughborough, Leicestershire, UK Efficient drug delivery is.
P A Jinks 3M Drug Delivery Systems Loughborough Leicestershire LE11 1EP Driven by the need for compliance to the Montreal Protocol (1), most MDI formulations.
John Simons 1, Herbert Chiou 1, Louis Sigtermans 1, Tom Robison 1, Debra Wright 1, Jacqueline Ganser 1, Steve Stein 1, Les Harrision 1, Paul Ratner 2 1.
Andy Cooper and Chris Blatchford 3M Drug Delivery Systems Ltd, Loughborough, Leicestershire, LE11 1EP Text Here – Body copy will vary in size depending.
P Bainbridge and P A Jinks 3M Drug Delivery Systems Loughborough Leicestershire LE11 1EP Text Here – Body copy will vary in size depending on how much.
SEMINAR ON PRESENTED BY BRAHMABHATT BANSARI K. M. PHARM PART DEPARTMENT OF PHARMACEUTICS AND PHARMACEUTICAL TECHNOLGY L. M. COLLEGE OF PHARMACY.
3M Drug Delivery Systems 3 Introduction The headspace of pressurized metered dose inhaler (MDI) canisters is filled by the vapor of volatile components,
Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Dose Content Uniformity: Parametric Tolerance Interval Approach.
3M Drug Delivery Systems 3 Introduction A family of hydrofluoroalkane-compatible excipients based on oligomeric lactic acid (OLA) has been proposed for.
Taper DPI FeatureImpact Efficacy Safety Compliance Cost High Efficiency  Equivalent lung dose achieved in- vitro with approximately 50% lower delivered.
Lesley Williams, Victoria Velasco, Dan Heyworth & Lisa Bradley 3M Health Care Ltd, Up Brooks, Clitheroe, Lancashire, BB7 1NX, England 3 Drug Delivery Systems.
Integration of Excipients into the Design of Experiments for Pharmaceutical Product and Design Space Development Chris Moreton, Ph.D. FinnBrit Consulting.
S. P. Mazumdar, D. K.Kundu*, A. R.Saha and Debjani Ghosh Crop Production Division ICAR-Central Research Institute of Jute and Allied Fibres, Barrackpore,
Thomas Bell and Andy Cooper 3M Drug Delivery Systems Ltd, Loughborough, Leicestershire, LE11 1EP 3M Drug Delivery Systems Monitoring of Droplet Size Changes.
Author : Development and characterization of Budesonide pressurized metered dose inhaler (pMDI) using gamma scintigraphy Sharma.
Introduction Methodology Results Conclusion Reference
KJ Hansen, JK Simons, TA Peterson
Comparison of Pharmaceutical Performance
Date of download: 10/19/2017 Copyright © ASME. All rights reserved.
The Impact of Extrusion Processes on Drug Burst Release from PLGA
Rahul Kumar Verma1, Hooman Yari and Lucila Garcia-Contreras1 
Chapter 3 Administration of Aerosolized Agents
Aerosol Drug Therapy Copyright © 2013, 2009, 2003, 1999, 1995, 1990, 1982, 1977, 1973, 1969 by Mosby, an imprint of Elsevier Inc.
Micrometrics. It is the science and technology of small particles. Knowledge and control of the size and the size range of particles are of significant.
RESULTS AND DISCUSSION
Quality control Lecture 1.
The Aerosol Drug Management Improvement Team
14 Design of Experiments with Several Factors CHAPTER OUTLINE
Presentation transcript:

3M Drug Delivery Systems 3 Introduction A combination MDI product has been developed containing two active drug substances (designated as A and B) in solution, 15% w/w ethanol as a co-solvent, a non-volatile mineral acid as a stabilizer, and HFA-134a as a propellant. The objective of this study was to assess the influences of drug, ethanol and acid concentration on the pharmaceutical performance of the product in order to assess the impact of manufacturing variability and to establish appropriate product specifications. Shuguang Hou, Todd Alband, Kimberly Kriesel, Lisa Dick and David Heisler 3M Drug Delivery Systems Division, 3M Center Building 260-4N-12, St Paul, MN The Influence of Formulation Factors on the Pharmaceutical Performance of a Solution Metered Dose Inhaler Product Results Dose Delivery:The delivered dose is defined as the drug amount collected downstream from the mouthpiece of the actuator. For both active drugs A and B, all formulations delivered within ± 20% of their target dose over the ethanol and acid concentration variability in the tested ranges studied (Table 2). The FDA guidance suggests that the dose content should not be outside of % of label claim (2). The delivered dose of both drugs A and B decreased following an increase in ethanol concentration in the formulations. This is primarily due to the decrease in formulation density following the increase in ethanol concentration, which results in a reduced shot weight and drug mass delivered per actuation. The acid level did not influence the delivered dose for either active drugs. The delivered dose of drug A was not affected by the concentration of drug B either. The delivered dose of drug B was proportional to its concentration in the formulations. Conclusions The dose delivery and particle size distribution of a solution HFA MDI product were influenced by the ethanol and drug concentration in the formulation. The non- volatile mineral acid did not have an effect on the pharmaceutical performance. Methods Two separate 2 2 factorial experiments, shown in Table 1, were designed to assess the influence of drug B, ethanol and acid concentration on MDI product performance. The concentration of drug A was 1 mcg per actuation in all the tested formulations, while drug B concentration was varied from 100 mcg to 200 mcg per actuation. The ethanol and acid concentrations were assessed at  20% and  50% of their respective target levels. A total of 12 formulations were prepared, including 2 duplicate target composition formulations at each concentration level for drug B. All formulations were filled in 3M aluminum 15- mL canisters with Bespak BK µL valves. Testing was conducted using Bespak 0.22 mm orifice diameter actuators. The dose delivery was tested using a dose unit spray apparatus (DUSA) tube and the particle size distribution was measured using Andersen cascade impactor (ACI). The flow rate was 28.3 liters per minute for both tests (1). The drug content was assayed by validated HPLC methods with UV detection. The method precision for delivered dose and fine particle dose is 3.2% and 6.8% relative standard deviation (RSD), respectively. The method limit of quantitation (LOQ) is 0.2 mcg and 0.4 mcg per actuation, respectively, for drugs A and B. References 1. USP24 General Chapters, FDA Draft Guidance for Industry, “Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products”, October Stein, S.W. and Myrdal, P.B. (2004), J. Pharm. Sci., 93 (8), Drug B Conc. (mcg/act.) Ethanol Conc. (% w/w)Acid Conc. (% w/w) Lot A1Lot D1Low Lots C11 & C12Target Lot B1Lot E1High 200 Lot A2Lot D2Low Lots C21 & C22Target Lot B2Lot E2High Table 1 Factorial Design of Experiments Particle Size Distribution: The fine particle fraction (FPF) and mass median aerodynamic diameter (MMAD) for both drugs A and B were identical, as shown in Table 2 and Figure 1, indicating the co- deposition of the two active drugs in the solution formulation. The FPF was influenced by both the ethanol and drug B concentration in the formulation. As the ethanol concentration was increased, the FPF decreased and more residual drug was observed in the actuator mouthpiece and USP throat inlet. A lower FPF was observed for formulations with a higher drug B concentration. The drug concentration effect on the FPF was less obvious for formulations with higher ethanol concentration levels, such as lots E1 and E2, suggesting that the ethanol concentration plays a more prominent role on the particle size distribution of solution MDIs. The MMAD for both active drugs was not sensitive to the ethanol concentration levels in the formulation. It is believed that the depositions of large particles in the actuator mouthpiece and USP throat inlet mask the ethanol effect on MMAD (3). A larger MMAD was observed for all formulations with a higher drug B concentration, shown in Figure 1. Theoretically the MMAD is proportional to the total non-volatile drug concentration to the 1/3 power (3). The ratio of measured MMAD between these two drug concentration formulations (MMAD 200mcg/act / MMAD 100mcg/act ) was 1.24, which agreed well with the theoretical ratio of LotDelivered Dose (mcg/act.) FPF (%) Residual in Actuator and Throat (mcg/act.) Drug ADrug BDrug ADrug BDrug ADrug B A10.95 (0.03)95 (3)60.2 (0.6)60.8 (1.4)0.43 (0.02)38 (2) B10.90 (0.05)90 (2)57.2 (1.8)56.5 (1.9)0.40 (0.02)39 (1) C (0.01)92 (2)49.0 (2.7)49.2 (2.6)0.48 (0.01)48 (5) C (0.03)91 (4)48.7 (2.3)48.2 (2.5)0.49 (0.02)47 (3) D10.85 (0.04)85 (4)42.9 (2.0)42.9 (1.8)0.51 (0.01)49 (1) E10.80 (0.03)85 (2)40.1 (2.5)40.2 (2.5)0.54 (0.05)51 (5) A20.89 (0.06)179 (12)54.6 (2.0)55.0 (1.9)0.46 (0.01)91 (3) B20.88 (0.02)184 (4)53.5 (1.8)53.3 (1.5)0.48 (0.02)93 (4) C (0.02)182 (3)44.0 (2.0)43.4 (1.4)0.51 (0.01)104 (4) C (0.02)180 (4)44.9 (0.9)44.6 (0.9)0.54 (0.01)106 (1) D20.83 (0.02)173 (4)40.2 (2.3)37.9 (2.0)0.55 (0.02)111 (4) E20.84 (0.04)175 (4)40.8 (1.1)39.9 (1.2)0.53 (0.02)101 (5) Table 2 Summary of Dose Delivery and Particle Size Distribution Figure 1 Plot of MMAD versus Drug B Concentration Mean (Standard Deviation) n = 15 for delivered dose and n = 5 for particle size distribution